Eye experts at the 2023 American Society of Retina Specialists meeting stress early intervention, the lifelong commitment to retinal therapeutics, regular checkups, and prevention for optimal eye health.
Last week's FDA approval of avacincaptad pegol marked the second approved treatment for geographic atrophy in 2023. Here, 4 retina specialists discuss the complement inhibitor and what it could represent for patients with GA.
A relationship was found between geographic atrophy growth and worsening vision loss in a post hoc analysis of the phase 3 GATHER1 and GATHER2 pivotal clinical trials investigating avacincaptad pegol, according to Iveric Bio.
Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.